Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is
the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the …

Cancer cannot be controlled by the usage of drugs alone, and thus, nanotechnology is an
important technique that can provide the drug with an impetus to act more effectively. There …

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare type of primary liver
malignancy. Among the risk factors, hepatitis B and hepatitis C virus infections, cirrhosis, and …

Hepatocholangiocarcinoma, fibrolamellar carcinoma, hepatic haemangioendothelioma and
hepatic angiosarcoma represent less than 5% of primary liver cancers. Fibrolamellar …

Background & Aims Management of combined hepatocellular-cholangiocarcinoma (cHCC-
CCA) is not well-defined. Therefore, we evaluated the management of cHCC-CCA using an …

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a unique type of liver tumor
that contains both hepatocellular carcinoma and cholangiocarcinoma components within a …

The low incidence of combined hepatocellular cholangiocarcinoma (cHCC-CCA) is an
important factor limiting research progression. Our study extensively included nearly three …

Simple Summary Combined hepatocellular-cholangiocarcinoma is a rare and aggressive
liver tumor that exhibits both hepatocytic and biliary differentiation. In this review we address …

In recent years, owing to advances in our understanding of hepatocarcinogenesis, rare
primary liver cancers (PLCs), including combined hepatocellular-cholangiocarcinoma …

Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare form of primary hepatic
collision tumor, with an incidence ranging from 0.4 to 14.2%. Given the diagnostic …